Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting

International Journal of Collaborative Research on Internal Medicine and Public Health

Volumn 2, Issue 5, 2010, Pages 142-156

  Ghosh, Sayantani ^a   Dey, Saugat ^a  

^a BANKURA SAMMILANI MEDICAL COLLEGE   (India)

Author keywords

5 HT3 receptor antagonist; Chemotherapy induced nausea and vomiting; Dexamethasone; Granisetron; Ondansetron; Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; ONDANSETRON; PALONOSETRON;

ADOLESCENT; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPOKALEMIA; INDIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 77955459314     PISSN: None     EISSN: 18404529     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kamm, M.A. Review article: the complexity of drug development for irritable bowel syndrome, Alimentari Pharmacology & Therapeutics. 2001; 16 (3): 343-351.
2. Laszlo J, Lucas V S. Emesis as a critical problem in chemotherapy. N Engl J Med 1981; 305:948-9.
3. Smith DB, Newlands ES, Rustin GJ, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatincontaining chemotherapy. Lancet. 1991; 338: 487-90.
4. Mertens WC, Higby DJ, Brown D, et al: Improving the care of patients with regard to chemotherapy-induced nausea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003; 21: 1373-1378.
5. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
6. Koo WH, Ang PT: Role of maintenance dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol. 1996; 7:71-74.
7. American Society of Clinical Oncology. 2006 update of the ASCO recommendations for antiemetics in oncology: Guideline summary. Retrieved November 7, 2007, from http://jop.ascopubs.org/cgi/content/full/2/4/193.
8. Multinational Association of Supportive Care in Cancer. Consensus conference on antiemetic therapy. Retrieved November 7, 2007, from http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Antiemesis [version 1. 2007]. Retrieved April 23, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
10. Multinational Association of Supportive Care in Cancer (MASCC) Antiemetic Guideline Committee. Antiemetic guidelines from the consensus conference on antiemetic therapy. Perugia International Cancer Conference VII, March 29-31, 2004, Perugia, Italy.
11. Seynaeve C, Schuller J etal. Comparison of the antiemetic efficacy of different doses of ondansetron given as either a continuous infusion or a single intravenous dose, in acute cisplatin induced emesis: a multicentre, double-blind, randomized, parallel group study. Br J Cancer. 1992; 66: 1992-7.
12. Minami M. Granisetron: is there a dose-response effect on nausea and vomiting? Cancer Chemother Pharmacol. 2003; 52:89-98.
13. Masuda N, Sekine I, Kubota K, et al. A phase II dose-response study of palonosetron (PALO) in Japanese patients receiving highly emetogenic chemotherapy (HEC)-Palo Japanese Cooperative Study Group. Ann Oncol. 2006; 17 (suppl 9): ix303.
14. Tabei T, Inoue K, Segawa Y, et al. A phase II dose-response study of palonosetron (PALO) in Japanese patients receiving moderately emetogenic chemotherapy (MEC)-Palo Japanese Cooperative Study Group. Ann Oncol. 2006; 17 (suppl 9): 302-3.
15. Blower P.R. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications, Cancer J. 2002, 8, 405-414.
16. Wong EH, Clark R, Leung E et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995; 114: 851-859.
17. Van Wijngaarden I, Tulp MTM, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol. 1990; 188: 301-312.
18. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-82.
19. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose ranging clinical study. Ann Oncol 2004; 15: 330-37.
20. ®(ondansetron hydrochloride injection) prescribing information. Research Triangle Park, NC: GlaxoSmithKline 2001.
21. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-189.
22. ®(dolasetron mesylate injection) prescribing information. Bridgewater, NJ: Aventis Pharmaceuticals 2002.
23. ® (granisetron hydrochloride injection) prescribing information. Nutley, NJ: Roche Laboratories 2000.
24. Rojas C, Stathis M, Alt J, et al. Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT₃ receptor antagonists. J Clin Oncol 2007; 25 (18S): abstract 19583.
25. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-49.
26. Mitsue Saito, Kenjiro Aogi, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-24.
27. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-77.